Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term guidelines. Found 17 abstracts

Jones EA, Shuman AG, Egleston BL, Liu JC. Common Pitfalls of Head and Neck Research Using Cancer Registries. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2019 Aug;161(2):245-50.
Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, Kumar SK, Million L, von Mehren M, Benson AB. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019 Aug 02;30(10):1647-52.   PMCID: PMC6857604
Stack BC, Tolley NS, Bartel TB, Bilezikian JP, Bodenner D, Camacho P, Cox J, Dralle H, Jackson JE, Morris JC, Orloff LA, Palazzo F, Ridge JA, Scott-Coombes D, Steward DL, Terris DJ, Thompson G, Randolph GW. AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. Head & neck. 2018 Aug;40(8):1617-29.
Behrend SW. New guidelines for chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2014 Sep;41(5):559-60.   PMCID: No NIH funds
Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Apr;17(2):96-104.   PMCID: *
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 2012 Mar;124(3):563-8.   PMCID: PMC3278517
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011 Mar;22(3):515-23.   PMCID: PMC3105293
Miller-Samuel S, McDonald DJ, Weitzel JN, Santiago F, Martino MA, Namey T, Augustyn A, Mueller R, Forman A, Bradbury AR, Morris GJ. Variants of Uncertain Significance in Breast Cancer-Related Genes: Real-World Implications for a Clinical Conundrum. Part One: Clinical Genetics Recommendations. Seminars in Oncology. 2011 Aug;38(4):469-80.   PMCID: not NIH funded
Wong YN, Coups EJ. Correlates of Colorectal Cancer Screening Adherence Among Men Who have been Screened for Prostate Cancer. Journal of Cancer Education. 2011 Jun;26(2):301-7.   PMCID: PMC3098903
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Sprangers MA, Sloan JA, Barsevick A, Chauhan C, Dueck AC, Raat H, Shi QL, Van Noorden CJ, Geneqol Consortium. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of Life Research. 2010 Dec;19(10):1395-403.   PMCID: PMCID: PMC2977054
Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, MacAlpine K, Wright JJ, Oza AM. Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer. 2010 Jul;20(5):787-93.   PMCID: Not required
Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: Perspectives and issues on policy-guided health care. Pharmacotherapy. 2008 May;28(5):1S-15S.
Katz SJ, Lantz PM, Janz NK, Fagcrlin A, Schwartz K, Liu LH, Deapen D, Salem B, Lakhani I, Morrow M. Patient involvement in surgery treatment decisions for breast cancer. Journal of Clinical Oncology. 2005 Aug 20;23(24):5526-33.
Orleans CT, Hutchinson D. Tailoring Nicotine Addiction Treatments for Chemical Dependency Patients. Journal of substance abuse treatment. 1993 Mar;10(2):197-208.
Orleans CT, Ockene JK. Routine Hospital-Based Quit Smoking Treatment for the Postmyocardial Infarction Patient - an Idea Whose Time Has Come. Journal of the American College of Cardiology. 1993 Nov 15;22(6):1703-5.
Schoenbach VJ, Orleans CT, Wagner EH, Quade D, Salmon MA, Porter CQ. Characteristics of Smokers Who Enroll and Quit in Self-Help Programs. Health education research. 1992 Sep;7(3):369-80.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term guidelines

guidelines carcinoma progression intervention follow-up survival depression Ovarian cancer risk perspective initiation pharmacists' management smoking cessation program study design mastectomy strategies antigen Colorectal cancer screening reoperative united- trial NCD imatinib dose imatinib stromal tumor CA-125 checklist independent prognostic-factor abuse treatment unbalanced informed-consent primary peritoneal tobacco fatigue chemical dependency patients CMS Seer nicotine addiction solid her2 prevention residual disease society ca 125 quit-smoking randomized trial induction chemotherapy gastrointestinal Clinical implications change Bevacizumab phase-ii half-life tumors errors Network consensus teachable moment stage-iii trials darbepoetin alfa cigarettes Patient-reported outcomes Theory off-label drug use brca2 genes ca-15-3 EPOETIN prognostic-factors carriers Quality of life paclitaxel nilotinib Gemcitabine imatinib mesylate united-states stem-cell transplantation treatment outcomes smoking cessation cessation Centers for Medicare and Medicaid Services chemotherapy-induced peripheral neuropathy neoadjuvant chemotherapy cancer information p53 germline mutations Response assessment oncology CHEMOTHERAPY bevacizumab Breast neoplasm Circulating tumor cell-HER2-Metastasis Genetic variables renal-cell carcinoma solid tumors Sorafenib unclassified treatment alternatives ca125 response criteria markers self-rated health participation disease gist cancer registry role European Society of Medical Oncology CA125 rhoc-gtpase data analysis PDGFR-alpha ovarian-cancer decision-making Prostate cancer screening 1994 rd d-v343-p692 parathyroid anemia alfa kit family-history KIT platinum ANEMIA conservation therapy gene amplification patterns erythropoiesis-stimulating agents instructions stage-i statistical flaws stages of message smoking Health education Antiangiogenic associations surgery submission head and neck cancer Ncdb ESAs services task-force pitfalls anxiety national coverage determination variants pregnant-women National Comprehensive Cancer health positron-emission-tomography
Last updated on Friday, January 03, 2020